Toll Free: 1-888-928-9744

Seizures - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 201 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Seizures - Pipeline Review, H1 2016

Summary
Global Markets Direct's, 'Seizures - Pipeline Review, H1 2016', provides an overview of the Seizures pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seizures and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Seizures - The report reviews pipeline therapeutics for Seizures by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Seizures therapeutics and enlists all their major and minor projects - The report assesses Seizures therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Seizures Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Seizures - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Seizures Overview 8 Therapeutics Development 9 Pipeline Products for Seizures - Overview 9 Pipeline Products for Seizures - Comparative Analysis 10 Seizures - Therapeutics under Development by Companies 11 Seizures - Therapeutics under Investigation by Universities/Institutes 14 Seizures - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Seizures - Products under Development by Companies 19 Seizures - Products under Investigation by Universities/Institutes 23 Seizures - Companies Involved in Therapeutics Development 24 Adamas Pharmaceuticals, Inc. 24 Advicenne Pharma 25 Alexza Pharmaceuticals, Inc. 26 Biscayne Pharmaceuticals, Inc. 27 Catalyst Pharmaceutical Partners, Inc. 28 Eisai Co., Ltd. 29 GW Pharmaceuticals Plc 30 INSYS Therapeutics, Inc. 31 Marinus Pharmaceuticals, Inc. 32 Novartis AG 33 OPKO Health, Inc. 34 Pfizer Inc. 35 PTC Therapeutics, Inc. 36 RODES Inc. 37 Sage Therapeutics, Inc. 38 SciFluor Life Sciences, LLC 39 SK Biopharmaceuticals Co., Ltd. 40 Turing Pharmaceuticals AG 41 UCB S.A. 42 Ultragenyx Pharmaceutical Inc. 43 Upsher-Smith Laboratories, Inc. 44 Xenon Pharmaceuticals Inc. 45 XERIS Pharmaceuticals, Inc. 46 Zogenix, Inc. 47 Seizures - Therapeutics Assessment 48 Assessment by Monotherapy Products 48 Assessment by Target 49 Assessment by Mechanism of Action 52 Assessment by Route of Administration 54 Assessment by Molecule Type 56 Drug Profiles 58 ADS-4101 - Drug Profile 58 ADV-6208 - Drug Profile 59 ADV-6770 - Drug Profile 60 alprazolam - Drug Profile 61 AMPX-0079 - Drug Profile 63 ataluren - Drug Profile 64 BIS-001 - Drug Profile 68 brivaracetam - Drug Profile 69 Cannabidiol - Drug Profile 72 CCG-63802 - Drug Profile 74 CHEC-9 - Drug Profile 75 clobazam - Drug Profile 77 CPP-115 - Drug Profile 78 CUR-1916 - Drug Profile 80 diazepam - Drug Profile 81 diazepam - Drug Profile 82 Epidiolex - Drug Profile 83 everolimus - Drug Profile 86 fenfluramine hydrochloride - Drug Profile 92 fosphenytoin sodium - Drug Profile 93 ganaxolone - Drug Profile 94 lacosamide - Drug Profile 96 levetiracetam - Drug Profile 102 lorazepam - Drug Profile 105 magnesium valproate hydrate - Drug Profile 106 MB-003 - Drug Profile 107 midazolam hydrochloride - Drug Profile 108 Oligonucleotide for Dravet Syndrome - Drug Profile 109 perampanel - Drug Profile 110 pregabalin - Drug Profile 113 SAGE-217 - Drug Profile 115 SAGE-689 - Drug Profile 116 selurampanel - Drug Profile 117 sepranolone - Drug Profile 118 SF-0034 - Drug Profile 121 Small Molecule for Stroke and Epilepsy - Drug Profile 122 Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile 123 Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 124 Small Molecules for Seizures - Drug Profile 125 Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 126 TG-4155 - Drug Profile 128 TRP-001 - Drug Profile 129 TUR-004 - Drug Profile 130 TUR-005 - Drug Profile 131 UX-007 - Drug Profile 132 YKP-3089 - Drug Profile 134 Seizures - Recent Pipeline Updates 136 Seizures - Dormant Projects 188 Seizures - Discontinued Products 191 Seizures - Product Development Milestones 192 Featured News & Press Releases 192 Appendix 197 Methodology 197 Coverage 197 Secondary Research 197 Primary Research 197 Expert Panel Validation 197 Contact Us 197 Disclaimer 198
List of Tables
Number of Products under Development for Seizures, H1 2016 12 Number of Products under Development for Seizures - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Comparative Analysis by Unknown Stage Development, H1 2016 21 Products under Development by Companies, H1 2016 22 Products under Development by Companies, H1 2016 (Contd..1) 23 Products under Development by Companies, H1 2016 (Contd..2) 24 Products under Development by Companies, H1 2016 (Contd..3) 25 Products under Investigation by Universities/Institutes, H1 2016 26 Seizures - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 27 Seizures - Pipeline by Advicenne Pharma, H1 2016 28 Seizures - Pipeline by Alexza Pharmaceuticals, Inc., H1 2016 29 Seizures - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016 30 Seizures - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 31 Seizures - Pipeline by Eisai Co., Ltd., H1 2016 32 Seizures - Pipeline by GW Pharmaceuticals Plc, H1 2016 33 Seizures - Pipeline by INSYS Therapeutics, Inc., H1 2016 34 Seizures - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016 35 Seizures - Pipeline by Novartis AG, H1 2016 36 Seizures - Pipeline by OPKO Health, Inc., H1 2016 37 Seizures - Pipeline by Pfizer Inc., H1 2016 38 Seizures - Pipeline by PTC Therapeutics, Inc., H1 2016 39 Seizures - Pipeline by RODES Inc., H1 2016 40 Seizures - Pipeline by Sage Therapeutics, Inc., H1 2016 41 Seizures - Pipeline by SciFluor Life Sciences, LLC, H1 2016 42 Seizures - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 43 Seizures - Pipeline by Turing Pharmaceuticals AG , H1 2016 44 Seizures - Pipeline by UCB S.A., H1 2016 45 Seizures - Pipeline by Ultragenyx Pharmaceutical Inc., H1 2016 46 Seizures - Pipeline by Upsher-Smith Laboratories, Inc., H1 2016 47 Seizures - Pipeline by Xenon Pharmaceuticals Inc., H1 2016 48 Seizures - Pipeline by XERIS Pharmaceuticals, Inc., H1 2016 49 Seizures - Pipeline by Zogenix, Inc., H1 2016 50 Assessment by Monotherapy Products, H1 2016 51 Number of Products by Stage and Target, H1 2016 53 Number of Products by Stage and Mechanism of Action, H1 2016 56 Number of Products by Stage and Route of Administration, H1 2016 58 Number of Products by Stage and Molecule Type, H1 2016 60 Seizures Therapeutics - Recent Pipeline Updates, H1 2016 139 Seizures - Dormant Projects, H1 2016 191 Seizures - Dormant Projects (Contd..1), H1 2016 192 Seizures - Dormant Projects (Contd..2), H1 2016 193 Seizures - Discontinued Products, H1 2016 194



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify